Use of galanthamine for the treatment of pathological manifestations of the central nervous system based on intoxications with psychotropic substances

US8207159B2 · kind B2 · utility

Assignee

• HF Arzneimittelforschung GmbH · DE

Inventors

• Klaus Opitz · Münster, DE
• Joachim Moormann · Werne, DE
• Thomas Hille · Neuwied, DE
• Frank Becher · Koblenz, DE

Key dates

• Filing date: Apr 18, 2002
• Grant date: Jun 26, 2012
• Expiry date: Aug 14, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/36
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of galanthamine, as free base or as acid addition salt, for the treatment of cerebral, central nervous or psychiatric symptoms, defunctionalization manifestations or disorders occurring through intake of psychotropic substances as a consequence of occasional or chronic abuse of addictive substances, intoxicants or medicines, or as side effects of the use, especially repeated or prolonged, as intended of medicaments, or as an effect of use, in particular repeated or prolonged, not as intended of medicaments, or as a result of acute poisoning by psychotropic toxic substances, or as a result of chronic exposure to toxic substances with a psychotropic effect in humans or other vertebrates.